Abstract
Background: Insulin Autoimmune Syndrome (IAS) is a rare condition characterized by the combination of recurrent severely spontaneous hypoglycemia without evidence of exogenous insulin administration, high concentration of total serum insulin, and the presence of a high titer of insulin autoantibody (IAA). But now we describe a case with IAS caused by gliclazide and hardly occuring hypoglycemia.
Case Report: A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high. He had no exogenous insulin administration history. Switching antidiabetic therapy from gliclazide to acarbose and metformin, the patient’s serum insulin level and IAA decreased gradually. Accordingly, the glycemic control improved and there was no episode of hypoglycemia. Conclusion: Hence, clinicians should pay more attention to type 2 diabetic patients treated with gliclazide and detect their serum insulin concentration and IAA to exclude or diagnose IAS and perform the best therapeutic regimen to these patients.Keywords: Gliclazide, hypoglycemia, insulin autoantibodies, insulin autoimmune syndrome, insulin resistance.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature
Volume: 16 Issue: 4
Author(s): Xiu Feng, Lu Yuan, Yun Hu, Yunqing Zhu, Fan Yang, Lanlan Jiang, Rengna Yan, Yong Luo, Enhui Zhao, Chenxiao Liu, Ying Wang, Qi Li, Xin Cao, Qian Li and Jianhua Ma
Affiliation:
Keywords: Gliclazide, hypoglycemia, insulin autoantibodies, insulin autoimmune syndrome, insulin resistance.
Abstract: Background: Insulin Autoimmune Syndrome (IAS) is a rare condition characterized by the combination of recurrent severely spontaneous hypoglycemia without evidence of exogenous insulin administration, high concentration of total serum insulin, and the presence of a high titer of insulin autoantibody (IAA). But now we describe a case with IAS caused by gliclazide and hardly occuring hypoglycemia.
Case Report: A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high. He had no exogenous insulin administration history. Switching antidiabetic therapy from gliclazide to acarbose and metformin, the patient’s serum insulin level and IAA decreased gradually. Accordingly, the glycemic control improved and there was no episode of hypoglycemia. Conclusion: Hence, clinicians should pay more attention to type 2 diabetic patients treated with gliclazide and detect their serum insulin concentration and IAA to exclude or diagnose IAS and perform the best therapeutic regimen to these patients.Export Options
About this article
Cite this article as:
Feng Xiu, Yuan Lu, Hu Yun, Zhu Yunqing, Yang Fan, Jiang Lanlan, Yan Rengna, Luo Yong, Zhao Enhui, Liu Chenxiao, Wang Ying, Li Qi, Cao Xin, Li Qian and Ma Jianhua, Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature, Endocrine, Metabolic & Immune Disorders - Drug Targets 2016; 16 (4) . https://dx.doi.org/10.2174/1871530316666161223144558
DOI https://dx.doi.org/10.2174/1871530316666161223144558 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Drugs for Epidural Analgesia
Current Drug Targets GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Inhibitory Effect of Ebselen on Cerebral Acetylcholinesterase Activity In Vitro: Kinetics and Reversibility of Inhibition
Current Pharmaceutical Design Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Epidemiology, Prognosis and Prevention of Non-Traumatic Intracerebral Hemorrhage
Current Pharmaceutical Design Scleroderma Subsetting
Current Rheumatology Reviews Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Nutraceuticals as Lipid-Lowering Treatment in Pregnancy and Their Effects on the Metabolic Syndrome
Current Pharmaceutical Biotechnology Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews The Impact of Hypertension in Hemodialysis Patients
Current Hypertension Reviews Synthesis and Cytotoxic Evaluation for Some New Dihydropyrimidinone Derivatives for Anticancer Activity
Letters in Drug Design & Discovery Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry Therapeutic Potential of Drugs Targeting Pathophysiology of Intracerebral Hemorrhage: From Animal Models to Clinical Applications
Current Pharmaceutical Design Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews Induction of Propranolol Metabolism by Ginkgo biloba Extract EGb 761 in Rats
Current Drug Metabolism Genes and Hypertension
Current Pharmaceutical Design The Different Roles of The Channel-Kinases TRPM6 and TRPM7
Current Medicinal Chemistry Bariatric Surgery and it Effects on the Respiratory System
Current Respiratory Medicine Reviews Oxidative Stress Biology and Cell Injury During Type 1 and Type 2 Diabetes Mellitus
Current Neurovascular Research Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology